29 May 2018 07:00
29 May 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Four Lojuxta® Distribution Agreements Signed in Middle East
- Nine Lojuxta distribution agreements signed since November 2017
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce the signing of four further distribution agreements for Lojuxta® (lomitapide) across the Middle East, where the incidence of Homozygous Familial Hypercholesterolaemia ("HoFH"), the rare cholesterol disorder treated by Lojuxta, is relatively high.
The distribution agreements have been signed with Al Hafez Trading Establishment, which operates in Kuwait, Ebn Sina Medical, the leading medical organisation in Qatar, Muscat Pharmacy and Stores in Oman, and Goro Healthcare of the UAE and Bahrain. These agreements extend Amryt's distribution network in the region and will provide HoFH patients with better access to care.
Since November 2017 Amryt has signed nine new distribution agreements for Lojuxta. The Company holds an exclusive licence to sell Lojuxta across Europe, the Middle East, Turkey, Israel, Russia, the Commonwealth of Independent States, and the Balkan states. The recent expansion of the licence agreement has increased the total number of addressable patients in Amryt's territories by approximately 25%. Amryt generated revenues of €11.9m from sales of Lojuxta in 2017.
Joe Wiley, CEO of Amryt Pharma, commented:
"Driving Lojuxta's growth in new and existing territories is a core focus for Amryt in 2018. We are delighted to announce that we have further expanded our distribution network in the Middle East with additional agreements covering Kuwait, Qatar, Oman, the UAE and Bahrain. These agreements will ensure that we can respond effectively to physician requests for Lojuxta. The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes. We remain in discussions with other potential distribution partners as we continue to grow our network and market reach for Lojuxta."
Enquiries:
Amryt Pharma plc | +353 (1) 518 0200 |
Joe Wiley, CEO Rory Nealon, CFO/COO |
|
|
|
Shore Capital | +44 (0) 20 7408 4090 |
NOMAD and Joint Broker |
|
Edward Mansfield, Mark Percy, Daniel Bush
|
|
Davy | +353 (1) 679 6363 |
ESM Adviser and Joint Broker |
|
John Frain, Anthony Farrell
|
|
Stifel | +44 (0) 20 7710 7600 |
Joint Broker |
|
Jonathan Senior, Ben Maddison |
|
|
|
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Amber Fennell, Matthew Neal, Nicholas Brown |
About Amryt
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.
Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body and subsequent aggressive and premature narrowing and blocking of blood vessels. Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.
Amryt holds an exclusive licence to sell Lojuxta (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.
Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The European and US market opportunity for EB is estimated to be in excess of €1.3 billion.
Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.
In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.
For more information on Amryt, please visit amrytpharma.com